LBRX - NASDAQ
LB Pharmaceuticals Inc Common Stock
$27.95
+3.4%Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.
At a Glance
Live Snapshotlbrx
Common Stock
Last Annual Value
3.00K
3-Year CAGR
44%
5-Year CAGR
25%
10-Year CAGR
12%
LB Pharmaceuticals Inc Common Stock Competitors Analysis of Common Stock
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 LB Pharmaceuticals Inc Common Stock NASDAQ:LBRX | 3.00K | 44.2% | N/A | N/A | |
 Aura Biosciences, Inc. NASDAQ:AURA | 0.00 | N/A | N/A | N/A | |
 Annexon, Inc. NASDAQ:ANNX | 149.00K | 24.1% | 30.7% | N/A | |
 Editas Medicine, Inc. NASDAQ:EDIT | 10.00K | 7.7% | 7.4% | 9.6% | |
 Humacyte, Inc. NASDAQ:HUMA | 20.00K | 26.0% | 14.9% | N/A | |
 Kyverna Therapeutics, Inc. NASDAQ:KYTX | 1.00K | N/A | N/A | N/A | |
 Lyell Immunopharma, Inc. NASDAQ:LYEL | 2.00K | -56.9% | -39.2% | N/A | |
 Replimune Group, Inc. NASDAQ:REPL | 77.00K | 10.5% | 10.4% | N/A | |
 Tenaya Therapeutics, Inc. NASDAQ:TNYA | 21.00K | 44.2% | 39.3% | N/A | |
 Rocket Pharmaceuticals, Inc. NASDAQ:RCKT | 1.08M | 6.2% | 10.9% | 14.9% | |
 Korro Bio, Inc. NASDAQ:KRRO | 9.00K | 4.0% | -23.8% | N/A |
LB Pharmaceuticals Inc Common Stock Fair Value Envelope
Related Guides
Continue your LBRX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.